Tatva Chintan Pharma Chem Ltd Q1 FY2025 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/atgzdn1c7woyzhclqc5hfbpf.pdf

Key Takeaways


SDA Segment: The Price Shock

Chintan Shah: "I feel now the prices have really stabilized kind of, I would say, because I don't see there is any space to go below further. So, this is like a rock bottom prices, which we are seeing. In some of the cases, we have not seen such kind of prices in my 27 years of history."

Logistics Disruption

Chintan Shah: "But there may be some increase on account of freight, but that has been compensated by other saving in other expense. Krishan ji, the freight is impacting, but the major impact has started from end of June. Nearing 15th of June when this phenomenon has started."

Electrolyte Salts: The Inflection Point

Chintan Shah: "So, this is purely going into the automotive segment. So here we are visualizing slow commercialization to begin from early 2025 and real scale of commercialization eventually in 1 to 2 years so '26 and hitting the peak at 2027. This is what we expect."

New Product Pipeline Progress

Chintan Shah: "In terms of revenue, I would say we can cross INR200 crores. But honestly speaking, this is again a very large volume segment, very large, massive segment. But looking at our capacities in terms of electrolysis available at the plant and the number of electrolyzers which we can expand, I would say INR250 crores is a realistic number to it from this facility."

Margins: The Damage and the Recovery Path

Chintan Shah: "You can see this even in terms of our gross margins during this quarter. Possibly we still have an inventory of SDAs, which will have an impact of roughly about INR4.5 crores to INR5.5 crores in this Q2 as well. But that will end away all our old inventories and then we have newer raw materials coming in and selling at the new price."

Guidance & Commitments

CommitmentSpecificsTimeline
Revenue growthAt least 20% growth, can go up to 30%FY25 full year
EBITDA margin20% to 25%FY25 full year
SDA inventory drag cleared₹4.5-5.5 crore of old inventory sold throughEnd of Q2 FY25
Electrolyte volume uptickStrong uptick from customer's first automated battery lineQ3 FY25 (October)
Hybrid car battery electrolyte commercializationGradual pickupEarly 2025
Pharma intermediates commercializationTwo productsEarly 2025
Super capacitor electrolyte commercializationSlow start, real scale in 2026, peak in 2027Early 2025 onward
Polymer product dispatch for qualificationFirst product in Q2, second in Q3Q2/Q3 FY25
Distillation plant commercializedFrees reactor capacityEnd of August 2024
Freight rate normalizationDisruption to easeBeginning of September 2024
Plant utilizationReach 85%Q3 FY25
Zinc battery electrolyte plant-scale commercialization1 to 1.5 years from pilot scale~2026-2027
Polymer segment revenueCross ₹200 crores, reach ₹250 crores2-3 years
Electrolyte customer automated linesThree more lines over two yearsNext 2 years

Key Metrics

MetricQ1 FY25
Revenue from operations₹105.5 cr, 8% YoY decline, 7% QoQ growth
EBITDA₹12.6 cr, 41% YoY decrease, 19% QoQ decrease
EBITDA margin12.0%, decreased 670 bps YoY; COGS up 3.3%, employee expenses up 1.4%, other expenses up 2% YoY
PBT₹6.8 cr, vs ₹13.4 cr in Q1FY24
PAT₹5.2 cr, vs ₹9.5 cr in Q1FY24; PAT margin 4.9% vs 8.3% YoY
Other income₹1.2 cr, vs ₹1 cr in Q1FY24; includes FOREX gain of ₹0.56 cr
Exports₹65.7 cr, 62% of revenue; major countries include USA, UK, China, Germany, Japan, South Africa
PTC segment revenue₹29.7 cr, 9% QoQ growth, 6% YoY decline
Electrolyte Salts segment revenue₹1.3 cr, 3% QoQ decrease, 2% YoY growth
Pharma and Agro Intermediates and Specialty Chemicals revenue₹38.9 cr, 39% QoQ increase, 25% YoY growth
SDA segment revenue₹35 cr, 14% QoQ decline, 29% YoY decrease; volumes up 12% QoQ but sales realization dropped nearly 23%
SDA price reduction15% to 25% across various SDAs, driven by key raw material price decline
Full-year EBITDA margin guidance20% to 25%, reaffirmed despite Q1 performance
Reactor occupancy~77%, up from ~67% in previous quarter; expected to reach 85% by Q3 after distillation plant comes online
Ongoing capex₹35 cr to ₹40 cr, for distillation facility, bromine recovery plant, and storage; additional ₹50 cr to ₹70 cr planned subject to soil testing
Logistics cost impactEurope ~$5,000 per container, USA ~$6,500 to $7,500 per container; freight eating away $0.25 to $0.30 per kg
Delayed shipments~₹11 cr of material delayed, to be shipped through July and mid-August due to vessel unavailability
Old SDA inventory impact expected in Q2₹4.5 cr to ₹5.5 cr of margin pressure from consumption of high-cost SDA inventory